Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) has earned a consensus recommendation of "Reduce" from the eight analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $23.33.
A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of Amphastar Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday, November 9th. Barclays increased their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 18th. Wells Fargo & Company raised their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $25.00 and gave the stock an "equal weight" rating in a report on Friday, November 6th. Weiss Ratings raised shares of Amphastar Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, November 4th. Finally, Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday, August 7th.
Check Out Our Latest Analysis on Amphastar Pharmaceuticals
Insider Activity
In other news, CFO William Peters sold 12,631 shares of the business's stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $28.99, for a total value of $366,172.69. Following the sale, the chief financial officer directly owned 167,076 shares in the company, valued at $4,843,533.24. The trade was a 7.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Rong Zhou sold 10,000 shares of the business's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total value of $239,400.00. Following the completion of the sale, the executive vice president owned 169,203 shares in the company, valued at approximately $4,050,719.82. This trade represents a 5.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock worth $1,232,836 in the last three months. Company insiders own 29.60% of the company's stock.
Institutional Investors Weigh In On Amphastar Pharmaceuticals
Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its stake in shares of Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company's stock worth $39,726,000 after acquiring an additional 228,262 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Amphastar Pharmaceuticals by 14.1% in the third quarter. Marshall Wace LLP now owns 1,216,253 shares of the company's stock valued at $31,391,000 after purchasing an additional 149,931 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 17.8% in the third quarter. Goldman Sachs Group Inc. now owns 595,111 shares of the company's stock valued at $15,360,000 after purchasing an additional 89,751 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Amphastar Pharmaceuticals by 1.7% in the first quarter. Renaissance Technologies LLC now owns 553,900 shares of the company's stock worth $10,851,000 after purchasing an additional 9,200 shares in the last quarter. Finally, Systematic Financial Management LP lifted its position in shares of Amphastar Pharmaceuticals by 4.0% in the first quarter. Systematic Financial Management LP now owns 452,898 shares of the company's stock worth $8,872,000 after purchasing an additional 17,318 shares in the last quarter. Institutional investors own 65.09% of the company's stock.
Amphastar Pharmaceuticals Trading Up 2.1%
NASDAQ AMPH opened at $29.71 on Thursday. Amphastar Pharmaceuticals has a one year low of $16.65 and a one year high of $31.00. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.32 and a quick ratio of 2.36. The firm has a market cap of $1.27 billion, a P/E ratio of 13.57, a P/E/G ratio of 5.68 and a beta of 0.93. The stock's 50-day moving average is $26.33 and its 200-day moving average is $22.44.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.86 by $0.28. The business had revenue of $207.61 million during the quarter, compared to analyst estimates of $197.52 million. Amphastar Pharmaceuticals had a return on equity of 15.31% and a net margin of 13.27%. Sell-side analysts anticipate that Amphastar Pharmaceuticals will post 2.43 earnings per share for the current fiscal year.
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets generic and proprietary medicines, with a focus on products that can be technically challenging to produce. Its offerings include injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients. The company's products include treatments and emergency medicines such as enoxaparin, glucagon and epinephrine products. Amphastar also markets BAQSIMI, a nasal powder used to treat severe low blood sugar, and Primatene MIST, an over-the-counter asthma inhaler.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.